{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:35:09Z","timestamp":1793781309869,"version":"4.6.1"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007075","name":"European Society for Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.annonc.2026.09.015","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T08:18:48Z","timestamp":1792052328000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Gastric and oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up"],"prefix":"10.1016","author":[{"given":"S.-E.","family":"Al-Batran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bencivenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Crosby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Dinis-Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Huguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Lordick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lorenzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Martinez","family":"Ciarpaglini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.L.","family":"Obermannova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Piessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Shitara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Smyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.C.T.","family":"van Grieken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Zaanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ducreux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2026.09.015_bib1","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.critrevonc.2017.12.019","article-title":"ECCO essential requirements for quality cancer care: Oesophageal and gastric cancer","volume":"122","author":"Allum","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"10.1016\/j.annonc.2026.09.015_bib2","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41416-019-0515-5","article-title":"Can PD-L1 expression evaluated by biopsy sample accurately reflect its expression in the whole tumour in gastric cancer?","volume":"121","author":"Yamashita","year":"2019","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.annonc.2026.09.015_bib3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13000-017-0616-5","article-title":"Tumor containing fragment number influences immunohistochemistry positive rate of HER2 in biopsy specimens of gastric cancer","volume":"12","author":"Xu","year":"2017","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.annonc.2026.09.015_bib4","unstructured":"Carneiro F, Fukayama M, Grabsch H, et al. WHO Classification of Tumours Editorial Board. Digestive system tumours. WHO classification of tumours series, Lyon: International Agency for Research on Cancer. 2017:85\u201395."},{"key":"10.1016\/j.annonc.2026.09.015_bib5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/apm.1965.64.1.31","article-title":"The two histological main type esophagogastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification","volume":"64","author":"Lauren","year":"1965","journal-title":"Acta Pathol Microbiol Scand"},{"issue":"7636","key":"10.1016\/j.annonc.2026.09.015_bib6","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nature20805","article-title":"Integrated genomic characterization of oesophageal carcinoma","volume":"541","year":"2017","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.annonc.2026.09.015_bib7","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/nm.3850","article-title":"Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes","volume":"21","author":"Cristescu","year":"2015","journal-title":"Nat Med"},{"issue":"13","key":"10.1016\/j.annonc.2026.09.015_bib8","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1200\/JCO.20.02761","article-title":"HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study","volume":"39","author":"Haffner","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.09.015_bib9","article-title":"PD-L1 Immunohistochemistry in Gastric Cancer: Comparison of Combined Positive Score and Tumor Area Positivity Across 28-8, 22C3, and SP263 Assays","volume":"8","author":"Klempner","year":"2024","journal-title":"JCO Precis Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2026.09.015_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100154","article-title":"High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma","volume":"36","author":"Robert","year":"2023","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1016\/j.annonc.2026.09.015_bib11","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/his.14775","article-title":"High interobserver and intraobserver reproducibility among pathologists assessing PD-L1 CPS across multiple indications","volume":"81","author":"Nuti","year":"2022","journal-title":"Histopathology"},{"key":"10.1016\/j.annonc.2026.09.015_bib12","volume":"35","author":"Kang","year":"2024","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2026.09.015_bib13","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/jamaoncol.2021.0275","article-title":"Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials","volume":"7","author":"Chao","year":"2021","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2026.09.015_bib14","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1200\/JCO.22.00686","article-title":"Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair\/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study","volume":"41","author":"Andr\u00e9","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2026.09.015_bib15","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.annonc.2024.11.016","article-title":"Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO","volume":"36","author":"Raimondi","year":"2025","journal-title":"Ann Oncol"},{"issue":"Suppl 12","key":"10.1016\/j.annonc.2026.09.015_bib16","doi-asserted-by":"crossref","first-page":"S1602","DOI":"10.21037\/jtd.2019.06.50","article-title":"Accuracy of endoscopic ultrasound in esophageal cancer staging","volume":"11","author":"Krill","year":"2019","journal-title":"J Thorac Dis"},{"issue":"3","key":"10.1016\/j.annonc.2026.09.015_bib17","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/sj.bjc.6604200","article-title":"Staging investigations for oesophageal cancer: a meta-analysis","volume":"98","author":"van Vliet","year":"2008","journal-title":"Br J Cancer"},{"issue":"18","key":"10.1016\/j.annonc.2026.09.015_bib18","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1200\/JCO.2000.18.18.3202","article-title":"Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma","volume":"18","author":"Flamen","year":"2000","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2026.09.015_bib19","first-page":"980","article-title":"Detection of distant metastases in esophageal cancer with (18)F-FDG PET","volume":"45","author":"Heeren","year":"2004","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1016\/j.annonc.2026.09.015_bib20","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1002\/bjs.9905","article-title":"Pragmatic staging of oesophageal cancer using decision theory involving selective endoscopic ultrasonography, PET and laparoscopy","volume":"102","author":"Findlay","year":"2015","journal-title":"Br J Surg"},{"issue":"10","key":"10.1016\/j.annonc.2026.09.015_bib21","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1177\/2050640619856459","article-title":"Screening for head and neck second primary tumors in patients with esophageal squamous cell cancer: A systematic review and meta-analysis","volume":"7","author":"van de Ven","year":"2019","journal-title":"United European Gastroenterol J"},{"issue":"1","key":"10.1016\/j.annonc.2026.09.015_bib22","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12957-017-1176-6","article-title":"Endoscopic ultrasonography compared with multidetector computed tomography for the preoperative staging of gastric cancer: a meta-analysis","volume":"15","author":"Nie","year":"2017","journal-title":"World J Surg Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2026.09.015_bib23","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2021.5340","article-title":"18F-Fludeoxyglucose-Positron Emission Tomography\/Computed Tomography and Laparoscopy for Staging of Locally Advanced Gastric Cancer: A Multicenter Prospective Dutch Cohort Study (PLASTIC)","volume":"156","author":"Gertsen","year":"2021","journal-title":"JAMA Surg"},{"issue":"9","key":"10.1016\/j.annonc.2026.09.015_bib24","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.ejso.2016.06.401","article-title":"Staging laparoscopy in gastric cancer to detect peritoneal metastases: A systematic review and meta-analysis","volume":"42","author":"Ramos","year":"2016","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2026.09.015_bib25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1477-7800-2-3","article-title":"Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer","volume":"2","author":"Harmon","year":"2005","journal-title":"Int Semin Surg Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2026.09.015_bib26","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/jso.26770","article-title":"Clinical impact of gastrectomy for gastric cancer patients with positive lavage cytology without gross peritoneal dissemination","volume":"125","author":"Kobayashi","year":"2022","journal-title":"J Surg Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2026.09.015_bib27","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12957-021-02351-x","article-title":"Gastric cancer with positive peritoneal cytology: survival benefit after induction chemotherapy and conversion to negative peritoneal cytology","volume":"19","author":"Valletti","year":"2021","journal-title":"World J Surg Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2026.09.015_bib28","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.clnu.2021.10.018","article-title":"ESPEN practical guideline: Home enteral nutrition","volume":"41","author":"Bischoff","year":"2022","journal-title":"Clin Nutr"},{"issue":"7","key":"10.1016\/j.annonc.2026.09.015_bib29","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1093\/bjs\/znab078","article-title":"Supervised exercise after oesophageal cancer surgery: the PERFECT multicentre randomized clinical trial","volume":"108","author":"van Vulpen","year":"2021","journal-title":"Br J Surg"},{"issue":"1","key":"10.1016\/j.annonc.2026.09.015_bib30","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1186\/s13063-020-04311-4","volume":"21","author":"Tully","year":"2020","journal-title":"Trials"},{"issue":"6","key":"10.1016\/j.annonc.2026.09.015_bib31","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.jgo.2019.04.004","article-title":"The performance of three oncogeriatric screening tools - G8, optimised G8 and CARG - in predicting chemotherapy-related toxicity in older patients with cancer. A prospective clinical study","volume":"10","author":"Kotzerke","year":"2019","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.annonc.2026.09.015_bib32","unstructured":"European Medicines Agency. EMA recommendations on DPD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine. Available at https:\/\/www.ema.europa.eu\/en\/documents\/press-release\/ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-flucytosine_en.pdf. Accessed June 3, 2025."},{"key":"10.1016\/j.annonc.2026.09.015_bib33","unstructured":"Amin MB, Edge S, Greene F, et al., eds. AJCC Cancer Staging Manual. 8th ed. New York: Springer International Publishing; 2017."},{"key":"10.1016\/j.annonc.2026.09.015_bib34","unstructured":"Union for International Cancer Control. Brierley JD, Giuliani M, O'Sullivan B, et al., eds. TNM Classification of Malignant Tumours. 9th ed. Hoboken, New Jersey, USA: John Wiley & Sons, Inc.; 2025."},{"issue":"6","key":"10.1016\/j.annonc.2026.09.015_bib35","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1055\/a-1811-7025","article-title":"Endoscopic submucosal dissection for superficial gastrointestinal lesions: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2022","volume":"54","author":"Pimentel-Nunes","year":"2022","journal-title":"Endoscopy"},{"issue":"19","key":"10.1016\/j.annonc.2026.09.015_bib36","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1200\/JCO.19.02483","article-title":"Implementation of Minimally Invasive Esophagectomy From a Randomized Controlled Trial Setting to National Practice","volume":"38","author":"Markar","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2026.09.015_bib37","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1097\/SLA.0000000000005023","article-title":"Robot-assisted Versus Conventional Minimally Invasive Esophagectomy for Resectable Esophageal Squamous Cell Carcinoma: Early Results of a Multicenter Randomized Controlled Trial: the RAMIE Trial","volume":"275","author":"Yang","year":"2022","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.annonc.2026.09.015_bib38","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1056\/NEJMoa1805101","article-title":"Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer","volume":"380","author":"Mariette","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.annonc.2026.09.015_bib39","article-title":"Laparoscopic or open abdominal surgery with thoracotomy for patients with oesophageal cancer: ROMIO randomized clinical trial","volume":"111","year":"2024","journal-title":"Br J Surg"},{"issue":"18","key":"10.1016\/j.annonc.2026.09.015_bib40","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1200\/JCO.20.03614","article-title":"Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial","volume":"39","author":"Eyck","year":"2021","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.annonc.2026.09.015_bib41","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"},{"issue":"16_suppl","key":"10.1016\/j.annonc.2026.09.015_bib42","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.4000","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC\/GEJC) following neoadjuvant chemoradiotherapy (CRT): First results of overall survival (OS) from CheckMate 577","volume":"43","author":"Kelly","year":"2025","journal-title":"J Clin Oncol"},{"issue":"10447","key":"10.1016\/j.annonc.2026.09.015_bib43","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0140-6736(24)00745-1","article-title":"Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial","volume":"404","author":"Kato","year":"2024","journal-title":"Lancet"},{"issue":"10447","key":"10.1016\/j.annonc.2026.09.015_bib44","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0140-6736(24)01084-5","article-title":"Neoadjuvant therapy for oesophageal cancer: refining the armamentarium","volume":"404","author":"Al-Batran","year":"2024","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.annonc.2026.09.015_bib45","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S1470-2045(14)70028-2","article-title":"Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5\/ACCORD17): final results of a randomised, phase 2\/3 trial","volume":"15","author":"Conroy","year":"2014","journal-title":"Lancet Oncol"},{"issue":"25","key":"10.1016\/j.annonc.2026.09.015_bib46","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1200\/JCO.20.03697","article-title":"Randomized Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer (ARTDECO Study)","volume":"39","author":"Hulshof","year":"2021","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.annonc.2026.09.015_bib47","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1200\/JCO.20.03697","article-title":"Randomized study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer (ARTDECO study)","volume":"39","author":"Hulshof","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2026.09.015_bib48","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.ijrobp.2021.07.045","article-title":"Exclusive chemoradiotherapy with or without radiation dose escalation in esophageal cancer: multicenter phase 2\/3 randomized trial CONCORDE (PRODIGE-26)","volume":"111","author":"Crehange","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"10.1016\/j.annonc.2026.09.015_bib49","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1158\/1078-0432.CCR-21-3843","article-title":"A Phase III Multicenter Randomized Clinical Trial of 60 Gy versus 50 Gy Radiation Dose in Concurrent Chemoradiotherapy for Inoperable Esophageal Squamous Cell Carcinoma","volume":"28","author":"Xu","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.annonc.2026.09.015_bib50","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1055\/a-2176-2440","article-title":"Diagnosis and management of Barrett esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Guideline","volume":"55","author":"Weusten","year":"2023","journal-title":"Endoscopy"},{"issue":"5","key":"10.1016\/j.annonc.2026.09.015_bib51","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/SLA.0000000000006011","article-title":"Impact of the Surgical Approach for Neoadjuvantly Treated Gastroesophageal Junction Type II Tumors: A Multinational, High-volume Center Retrospective Cohort Analysis","volume":"278","author":"Wirsik","year":"2023","journal-title":"Ann Surg"},{"key":"10.1016\/j.annonc.2026.09.015_bib52","doi-asserted-by":"crossref","unstructured":"Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). Gastric Cancer. 2023;26(1):1-25.","DOI":"10.1007\/s10120-022-01331-8"},{"issue":"10","key":"10.1016\/j.annonc.2026.09.015_bib53","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1001\/jamasurg.2022.2749","article-title":"Laparoscopic vs Open Distal Gastrectomy for Locally Advanced Gastric Cancer: 5-Year Outcomes of the KLASS-02 Randomized Clinical Trial","volume":"157","author":"Son","year":"2022","journal-title":"JAMA Surg"},{"issue":"9","key":"10.1016\/j.annonc.2026.09.015_bib54","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1200\/JCO.20.01540","article-title":"Laparoscopic Versus Open Gastrectomy for Gastric Cancer (LOGICA): A Multicenter Randomized Clinical Trial","volume":"39","author":"van der Veen","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2026.09.015_bib55","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1097\/SLA.0000000000004466","article-title":"Assessment of Robotic Versus Laparoscopic Distal Gastrectomy for Gastric Cancer: A Randomized Controlled Trial","volume":"273","author":"Lu","year":"2021","journal-title":"Ann Surg"},{"issue":"10184","key":"10.1016\/j.annonc.2026.09.015_bib56","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.annonc.2026.09.015_bib57","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"van Hagen","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.annonc.2026.09.015_bib58","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa2409408","article-title":"Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer","volume":"392","author":"Hoeppner","year":"2025","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.annonc.2026.09.015_bib59","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1056\/NEJMoa2405195","article-title":"Preoperative Chemoradiotherapy for Resectable Gastric Cancer","volume":"391","author":"Leong","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.annonc.2026.09.015_bib60","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.annonc.2024.10.829","volume":"36","author":"Lordick","year":"2025","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2026.09.015_bib61","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2503701","article-title":"Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer","volume":"393","author":"Janjigian","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annonc.2026.09.015_bib62","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/S0140-6736(26)01254-7","volume":"408","author":"Janjigian","year":"2026","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.annonc.2026.09.015_bib63","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1200\/JCO.23.00975","article-title":"Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II\/III DANTE\/IKF-s633 Trial","volume":"42","author":"Lorenzen","year":"2024","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.annonc.2026.09.015_bib64","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jama.2010.534","article-title":"Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis","volume":"303","author":"Group","year":"2010","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.annonc.2026.09.015_bib65","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S1470-2045(18)30132-3","article-title":"Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial","volume":"19","author":"Cats","year":"2018","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2026.09.015_bib66","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.2011.39.1953","article-title":"Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial","volume":"30","author":"Lee","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2026.09.015_bib67","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.annonc.2020.11.017","article-title":"A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial","volume":"32","author":"Park","year":"2021","journal-title":"Ann Oncol"},{"issue":"35","key":"10.1016\/j.annonc.2026.09.015_bib68","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1200\/JCO.19.01124","article-title":"Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer","volume":"37","author":"Pietrantonio","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.09.015_bib69","doi-asserted-by":"crossref","first-page":"S1315","DOI":"10.1016\/j.annonc.2023.10.074","article-title":"LBA73 Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC\/GEJC): Interim results of the global, phase III MATTERHORN study","volume":"34","author":"Janjigian","year":"2023","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2026.09.015_bib70","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","article-title":"Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study","volume":"25","author":"Shitara","year":"2024","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2026.09.015_bib71","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1001\/jamaoncol.2021.0848","article-title":"Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer: The GO2 Phase 3 Randomized Clinical Trial","volume":"7","author":"Hall","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annonc.2026.09.015_bib72","doi-asserted-by":"crossref","unstructured":"Kato K, Ajani J, Doki Y, et al. Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648. Ann Oncol. 2026.","DOI":"10.1016\/j.annonc.2026.08.001"},{"issue":"11","key":"10.1016\/j.annonc.2026.09.015_bib73","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","article-title":"Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Kato","year":"2019","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.annonc.2026.09.015_bib74","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1200\/JCO.21.01926","article-title":"Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study","volume":"40","author":"Shen","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2026.09.015_bib75","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14740338.2021.1955100","article-title":"The safety of current treatment options for advanced esophageal cancer after first-line chemotherapy","volume":"21","author":"Ikeda","year":"2022","journal-title":"Expert Opin Drug Saf"},{"issue":"9","key":"10.1016\/j.annonc.2026.09.015_bib76","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1200\/JCO.2007.13.9378","article-title":"Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie","volume":"26","author":"Al-Batran","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2026.09.015_bib77","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa073149","article-title":"Capecitabine and oxaliplatin for advanced esophagogastric cancer","volume":"358","author":"Cunningham","year":"2008","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.annonc.2026.09.015_bib78","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","article-title":"S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial","volume":"9","author":"Koizumi","year":"2008","journal-title":"Lancet Oncol"},{"issue":"31","key":"10.1016\/j.annonc.2026.09.015_bib79","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","article-title":"Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group","volume":"24","author":"Van Cutsem","year":"2006","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2026.09.015_bib80","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S1470-2045(25)00130-5","article-title":"TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trial","volume":"26","author":"Zaanan","year":"2025","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.annonc.2026.09.015_bib81","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S2468-1253(19)30083-4","article-title":"Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial","volume":"4","author":"Yamada","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.annonc.2026.09.015_bib82","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/annonc\/mdn166","article-title":"Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction","volume":"19","author":"Dank","year":"2008","journal-title":"Ann Oncol"},{"issue":"31","key":"10.1016\/j.annonc.2026.09.015_bib83","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1200\/JCO.2013.54.1011","volume":"32","author":"Guimbaud","year":"2014","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2026.09.015_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103962","article-title":"Immune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma: a series of patient-level meta-analyses in different programmed death-ligand 1 subgroups","volume":"9","author":"Leone","year":"2024","journal-title":"ESMO Open"},{"issue":"12","key":"10.1016\/j.annonc.2026.09.015_bib85","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"issue":"20","key":"10.1016\/j.annonc.2026.09.015_bib86","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1056\/NEJMoa2517729","article-title":"Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer","volume":"394","author":"Shitara","year":"2026","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.annonc.2026.09.015_bib87","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1056\/NEJMc2409512","article-title":"Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma","volume":"391","author":"Shitara","year":"2024","journal-title":"N Engl J Med"},{"issue":"35","key":"10.1016\/j.annonc.2026.09.015_bib88","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1200\/JCO.2012.48.5805","article-title":"Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial","volume":"31","author":"Hironaka","year":"2013","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2026.09.015_bib89","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol"},{"issue":"9911","key":"10.1016\/j.annonc.2026.09.015_bib90","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Fuchs","year":"2014","journal-title":"Lancet"},{"issue":"10142","key":"10.1016\/j.annonc.2026.09.015_bib91","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(18)31257-1","article-title":"Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial","volume":"392","author":"Shitara","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.annonc.2026.09.015_bib92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability\/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2026.09.015_bib93","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1056\/NEJMoa2503119","article-title":"Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer","volume":"393","author":"Shitara","year":"2025","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.annonc.2026.09.015_bib94","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S1470-2045(18)30739-3","article-title":"Trifluridine\/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"19","author":"Shitara","year":"2018","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2026.09.015_bib95","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1470-2045(15)00553-7","article-title":"Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial","volume":"17","author":"Fujitani","year":"2016","journal-title":"Lancet Oncol"},{"issue":"17_suppl","key":"10.1016\/j.annonc.2026.09.015_bib96","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA4001","volume":"42","author":"Al-Batran","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.09.015_bib97","unstructured":"Hoskin P eds. Radiotherapy Dose Fractionation. Fourth ed. London, UK: The Royal College of Radiologists; January 2024."},{"issue":"7","key":"10.1016\/j.annonc.2026.09.015_bib98","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1200\/JCO.20.01254","article-title":"Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer: A Phase III Randomized Controlled Trial","volume":"39","author":"Lu","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2026.09.015_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100092","article-title":"Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines","volume":"6","author":"Arends","year":"2021","journal-title":"ESMO Open"},{"issue":"9","key":"10.1016\/j.annonc.2026.09.015_bib100","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2026.09.015_bib101","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.annonc.2025.04.006","article-title":"ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0)","volume":"36","author":"Cherny","year":"2025","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2026.09.015_bib102","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1086\/321805","article-title":"Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients","volume":"33","author":"Dykewicz","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.annonc.2026.09.015_bib103","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1470-2045(23)00215-2","volume":"24","author":"Van Cutsem","year":"2023","journal-title":"Lancet Oncol"},{"issue":"25","key":"10.1016\/j.annonc.2026.09.015_bib104","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426067761?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426067761?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:22:33Z","timestamp":1792214553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753426067761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":104,"alternative-id":["S0923753426067761"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2026.09.015","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gastric and oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2026.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society for Medical Oncology. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}